NCI Drug Dictionary

The NCI Drug Dictionary contains technical definitions and synonyms for drugs/agents used to treat patients with cancer or conditions related to cancer. Each drug entry includes links to check for clinical trials listed in NCI's List of Cancer Clinical Trials.

SVN53-67/M57-KLH peptide vaccine
A peptide vaccine containing a 15-mer peptide (DLAQMFFCFKELEGW), with C to M alteration at amino acid position 57, derived from the anti-apoptosis protein survivin, and conjugated with keyhole limpet hemocyanin (KLH), with potential immunopotentiating and antineoplastic activities. Upon subcutaneous administration of SVN53-67/M57-KLH peptide vaccine, this peptide is able to bind both HMC class I and II molecules and may activate the immune system to mount a cytotoxic T-lymphocyte (CTL) as well as a T-helper cell response against survivin-expressing cancer cells. This may result in decreased tumor cell proliferation and ultimately tumor cell death. Survivin, a member of the inhibitor of apoptosis (IAP) family, expressed during embryonic development while absent in most normal adult cells, is upregulated in a variety of human cancers; its expression in tumors is associated with a more aggressive phenotype, decreased survival, and increased resistance to chemotherapy. KLH may enhance immune recognition and may promote an enhanced response. As SVN53-67 is weakly immunogenic in humans, the M57 alteration may lead to greater affinity towards HLA-A*0201 and thus an enhanced antitumor immune response. Check for active clinical trials using this agent. (NCI Thesaurus)